Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 10, 2018* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins
-
Mar 10, 2018* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone
-
Jan 8, 2018Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma
-
Dec 13, 2017High and durable response rate in disease without any FDA-approved therapies
-
Dec 11, 2017* First FDA-approved follow-on mealtime insulin
-
Dec 7, 2017Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments
